1103 Results for "

Bioavailability

" in MedChemExpress (MCE) Product Catalog:
Products (1103)

1103 Results for "Bioavailability" in MCE Product Catalog:

Cat. No.: HY-173059
CAS No.: 3029608-57-6
Target:  

CDK

Research Areas:  

Cancer

CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC50 of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC50 of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .
loading...
    loading...
Cat. No.: HY-189008
Target:  

Others

17β-HSD13-IN-1 is a selective 17β-HSD13 inhibitor with a human IC50 of 9 nM, high selectivity over 17β-HSD1, nanomolar cellular activity, broad pH solubility, extended rodent plasma mean residence times, and high oral bioavailability in Mus musculus. 17β-HSD13-IN-1 engages in hydrophobic interactions with specific active-site amino acids of its target enzyme. 17β-HSD13-IN-1 can be used for the research of metabolic dysfunction-associated steatohepatitis (mash) .
loading...
    loading...
Cat. No.: HY-B0531S
CAS No.: 2748541-63-9
Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-D1005I
CAS No.: 9003-11-6
Poloxamer L61 is a non-ionic triblock copolymer surfactant. Poloxamer L61 effectively achieves intracellular molecular delivery to cancer cells during photoacoustic molecular delivery, and maintains cell viability by promoting cell membrane resealing, thus avoiding irreversible damage caused by laser-induced membrane permeabilization. Poloxamer L61 is a key component of SP1017, a compound related to gene therapy, which regulates the interaction between DNA and extracellular matrix as well as cellular uptake, and significantly enhances the distribution and bioavailability of plasmid DNA in skeletal muscle. Poloxamer L61 can be used in studies on local or systemic therapeutic protein production .
loading...
    loading...
Cat. No.: HY-FL0003
Synonyms: Lipoplus 20%
Target:  

Others

Research Areas:  

Inflammation/Immunology

ω-3-Fish oil medium and long chain fat emulsion is composed of fish oil, soybean oil and medium-chain triglycerides, and can be used as a nutritional supplement. ω-3-Fish oil medium and long chain fat emulsion contains high levels of DHA and EPA, which have anti-inflammatory effects and are essential for nervous system development. The ω-6:ω-3 PUFA ratio is closer to the ideal bioavailable ratio for humans, providing the body with necessary energy and essential fatty acids, while inhibiting inflammation and protecting liver function.
loading...
    loading...
Cat. No.: HY-N2345R
CAS No.: 23567-23-9
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .
loading...
    loading...
Cat. No.: HY-W698249
CAS No.: 299-29-6
Target:  

Ferroptosis Bacterial

Research Areas:  

Cardiovascular Disease Infection

Ferrous gluconate is a highly water-soluble iron-containing agent with high bioavailability and bactericidal activity. As a non-heme iron, Ferrous gluconate is used for meat product fortification and improvement of iron deficiency anemia. Ferrous gluconate induces ferroptosis in E. coli through Fe 2+ infiltration, reactive oxygen species burst, lipid peroxidation and direct interaction with DNA. Ferrous gluconate also downregulates the SOS responsive transcriptional repressor LexA. In addition, Ferrous gluconate regulates multiple key pathways in E. coli such as fatty acid metabolism, iron-sulfur cluster assembly and pyruvate metabolism, and is applied in studies related to *E. coli* infection and iron deficiency anemia .
loading...
    loading...
Cat. No.: HY-144022
CAS No.: 96326-74-8
Purity:  ≥98.0%
Target:  

Liposome

Research Areas:  

Others

16:0 DAP is an ionizable cationic lipid. 1,2-dipalmitoyl-3-dimethylammonium-propane serves as a barcode lipid, enabling LC-MS quantification in ocular tissues .
loading...
    loading...
Cat. No.: HY-173268
CAS No.: 3051784-94-9
Target:  

TAM Receptor

Research Areas:  

Cardiovascular Disease Cancer

UNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-13238R
CAS No.: 1051375-16-6
Synonyms: S/GSK1349572 (Standard)
Research Areas:  

Infection

Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
loading...
    loading...
Cat. No.: HY-144392
CAS No.: 84212-49-7
AChE/BuChE-IN-1 (Compound 1), a chrysin derivative, is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.48 μM. AChE/BuChE-IN-1 inhibits acetylcholinesterase (AChE) with an IC50 of 7.16 μM. AChE/BuChE-IN-1 shows strong scavenging ·OH activities with a IC50 of 0.1674 μM. AChE/BuChE-IN-1 inhibits reactive oxygen species (ROS), Aβ1-42 aggregation (self-, Cu2+-induced, AChE-induced). AChE/BuChE-IN-1 has high BBB permeability and bioavailability and low cell toxicity. AChE/BuChE-IN-1 has the potential for Alzheimer' disease (AD) research .
loading...
    loading...
Cat. No.: HY-169177
CAS No.: 3047795-60-5
Target:  

JNK

Research Areas:  

Inflammation/Immunology

JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
loading...
    loading...
Cat. No.: HY-B0531R
CAS No.: 322-79-2
Triflusal (Standard) is the analytical standard of Triflusal (HY-B0531). This product is intended for research and analytical applications. Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-W207224
CAS No.: 287177-12-2
Target:  

MAP4K

F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
loading...
    loading...
Cat. No.: HY-112414
CAS No.: 216661-57-3
Target:  

TGF-β Receptor

Research Areas:  

Metabolic Disease Cancer

ALK2-IN-7 is a ALK2 (ACVR1) inhibitor. ALK2-IN-7 is applicable to studies related to BMP/ALK2 signaling, anemia associated with iron homeostasis imbalance, and multiple osteochondromas .
loading...
    loading...
Cat. No.: HY-100014R
CAS No.: 1905481-36-8
Research Areas:  

Cancer

KDM5A-IN-1 (Standard) is the analytical standard of KDM5A-IN-1 (HY-100014). This product is intended for research and analytical applications. KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .
loading...
    loading...
Cat. No.: HY-10847BR
CAS No.: 215804-67-4
Synonyms: SB-277011A hydrochloride (Standard)
SB-277011 hydrochloride (Standard) is the analytical standard of SB-277011 (hydrochloride) (HY-10847B). This product is intended for research and analytical applications. SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor (D3R) antagonist with Ki values of 10.7 nM and 11.2 nM at rodent and human D3R, respectively. SB-277011 hydrochloride displays 80- to 100-fold selectivity over other dopamine receptors with pKis of 8.0, 6.0, <5.2, and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively .
loading...
    loading...
Cat. No.: HY-119202
CAS No.: 357263-14-0
Synonyms: (S)-BMS-806
Target:  

HIV

Research Areas:  

Infection

(S)-BMS-378806 ((S)-BMS-806) is an orally bioavailable HIV-1 inhibitor with activity against gp120-CD4 interactions. (S)-BMS-378806 exhibits micromolar inhibition of HIV-1 gp120-CD4 binding. The design and synthesis of (S)-BMS-378806 was based on a comprehensive study of protein-ligand interactions, which guided the identification and design of novel symmetrical N,N'-disubstituted aminoureas and thioureas. (S)-BMS-378806, synthesized in aqueous media using microwave irradiation, was validated for its inhibitory activity in HIV-1 gp120-CD4 capture ELISA .
loading...
    loading...
Cat. No.: HY-13270R
CAS No.: 141430-65-1
Synonyms: E7010 (Standard)
ABT-751 (Standard) is the analytical standard of ABT-751. This product is intended for research and analytical applications. ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .
loading...
    loading...
Cat. No.: HY-13342AS
CAS No.: 2468771-43-7
Purity:  92.56%
Synonyms: YN968D1-d8 free base
Apatinib-d8 (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .
loading...
    loading...